SynthesisWorld journal of surgery2012
Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis.
Synthesis in World journal of surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 40 citations in OpenAlex.
- Conservative management of a delayed enterocutaneous fistula following emergency distal gastrectomy using sequential somatostatin analogues.Journal of surgical case reports · 2026Article
- Somatostatin-based therapies for external gastrointestinal fistulas: Updated meta-analysis of randomized clinical trials.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- The Role of Somatostatin in the Gastrointestinal Tract.Biology · 2025Review
- Effect of postoperative utilization of somatostatin on clinical outcome after definitive surgery for duodenal fistula.European journal of medical research · 2023Article
- Chronic intestinal failure and short bowel syndrome in Crohn's disease.World journal of gastroenterology · 2021Review
- Postoperative enterocutaneous fistulas: Management outcomes in 23 consecutive patients.Annals of medicine and surgery (2012) · 2021Article
- Surgical treatment of postoperative laparostomy and pyloroduodenostomy-Case report.International journal of surgery case reports · 2018Article
- Effect of Oral ω3-Polyunsaturated Fatty Acids as a Complement Management to Control Fistula Output and Inflammation in Patients With Digestive Fistula.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2017Article
- Enterocutaneous Fistula: Proven Strategies and Updates.Clinics in colon and rectal surgery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnterocutaneous fistulas are abnormal connections between the skin and gastrointestinal tract that most commonly occur after surgery. Somatostatin analogues have been used in their treatment. The objective of the present study was to determine if somatostatin analogues shorten the time to closure of postoperative enterocutaneous fistulas compared to placebo.
methodsWe searched Medline, EMBase, the Cochrane Central Register of Controlled Trials, as well as reference lists of textbooks and relevant articles for randomized controlled trials (RCT) comparing somatostatin analogues to control in the treatment of postoperative enterocutaneous fistulas. We systematically assessed trials for eligibility and validity, and extracted data in duplicate. We pooled data across studies using a random effects model.
resultsOur initial search yielded 720 studies, of which eight RCT ultimately met eligibility criteria and were included in this review. Somatostatin analogues significantly decreased the time to closure of fistulas compared to placebo {weighted mean difference (WMD)--6.37 days [95% confidence interval (CI) -8.33, -4.42]}. The duration of hospital stay was also significantly decreased with somatostatin analogue treatment [WMD--4.53 days (95% CI -8.29, -0.77)]. No difference in mortality was identified with somatostatin treatment [RR 0.87 (95% CI 0.49-1.55)].
conclusionsSomatostatin analogues appear to decrease the duration of enterocutaneous fistulas and duration of hospital stay, but no mortality benefit was identified. The quality of evidence for outcomes in this review ranged from low to moderate. Future large, blinded, RCT would be useful in improving the confidence in the treatment effects identified in this systematic review and meta-analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.